scholarly journals High-Dose Versus Weekly Cisplatin Definitive Chemoradiation Therapy for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma of the Head and Neck

2016 ◽  
Vol 94 (4) ◽  
pp. 895 ◽  
Author(s):  
C.A. Perez ◽  
M.J. Amsbaugh ◽  
W. Claudino ◽  
M. Yusuf ◽  
X. Wu ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Chemoradiation Therapy ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
High Dose ◽  
Definitive Chemoradiation ◽  
Weekly Cisplatin

High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 6074-6074 ◽  
Author(s):  
Cesar Augusto Perez ◽  
Xiaoyong Wu ◽  
Mark J. Amsbaugh ◽  
Wederson M. Claudino ◽  
Mehran Yusuf ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
High Dose ◽  
Definitive Chemoradiotherapy ◽  
Weekly Cisplatin

High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck

Oral Oncology ◽  
2017 ◽  
Vol 67 ◽  
pp. 24-28 ◽  
Author(s):  
Cesar Augusto Perez ◽  
Xiaoyong Wu ◽  
Mark J. Amsbaugh ◽  
Rahul Gosain ◽  
Wederson M. Claudino ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
High Dose ◽  
Definitive Chemoradiotherapy ◽  
Weekly Cisplatin

Association of Cystic Neck Metastases and Human Papillomavirus–Positive Oropharyngeal Squamous Cell Carcinoma

2009 ◽  
Vol 133 (11) ◽  
pp. 1798-1803
Author(s):  
Jonathan B. McHugh
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
High Risk ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Sexual Behaviors ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
Treatment Modalities ◽  
Neck Metastases

Abstract Human papillomavirus is an established cause of oropharyngeal squamous cell carcinoma. Similar to cervical cancer, these cancers are usually caused by high-risk human papillomavirus types 16 and 18 and are associated with high-risk sexual behaviors. Human papillomavirus–associated oropharyngeal squamous cell carcinoma typically affects the palatine and lingual tonsils and frequently results in cystic neck metastases. The histopathology of this subset of head and neck squamous cell carcinoma is unique and typically characterized by poorly differentiated, nonkeratinizing morphology with a basaloid appearance. These tumors occur in younger patients and are more often seen in nonsmokers compared with conventional oral cavity and oropharyngeal squamous cell carcinomas. The incidence of human papillomavirus–associated squamous cell carcinoma is increasing. Recognition of this unique clinicopathologic subset of head and neck carcinoma is important because these patients typically respond more favorably to organ-sparing treatment modalities and have an improved prognosis.

Weekly cisplatin and radiotherapy for low-risk human papillomavirus positive oropharyngeal squamous cell carcinoma (HPVOPC).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e17017-e17017
Author(s):  
Damien Urban ◽  
June Corry ◽  
Benjamin J. Solomon ◽  
Annette May Ling Lim ◽  
Tsien Fua ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
Low Risk ◽  
Weekly Cisplatin

Cisplatin every three weeks versus weekly cisplatin or carboplatin with definitive radiotherapy for squamous cell carcinoma of the head and neck is associated with improved overall survival in a representative national population.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 6536-6536
Author(s):  
Michael Gerard McCusker ◽  
Ranee Mehra ◽  
Jason K. Molitoris ◽  
Rodney Taylor ◽  
Kevin J. Cullen ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Hearing Loss ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
High Dose ◽  
Medicare Beneficiaries ◽  
Curative Radiotherapy ◽  
Weekly Cisplatin

6536 Background: For patients with primary untreated locally advanced head and neck squamous cell carcinoma (PULA-HNSCC), high dose once every 3 weeks cisplatin (HDC; 100 mg/m2) added to curative radiotherapy (RT) prolongs survival, but is associated with severe toxicities. Concurrent chemoradiation (CRT) with low dose weekly cisplatin (LDC; 30-40 mg/m2), carboplatin (C), or RT alone is often substituted for HDC. We estimated and compared overall survival (OS) and acquired toxicities among Medicare beneficiaries treated with CRT using HDC, LDC, C, or RT. Methods: Patients diagnosed from 2004-2011 with PULA-HNSCC (stages III-IVB AJCC 6th and 7th editions) of the oropharynx (OPC), hypopharynx (HP), or larynx (L) who received definitive RT or CRT were identified using the linked SEER-Medicare database. An analytic cohort of patients receiving CRT with HDC, LDC, or C was constructed using well-established eligibility criteria. OS was estimated and compared between patients grouped by treatment received utilizing a multivariable stratified propensity scores weighted Cox regression model, including demographic and disease characteristics. Toxicities were compared using exact common odds-ratio and Fisher’s tests. Results: We identified 1,335 patients that received RT: OPC (n = 731), HP (n = 174), or L (n = 430). Out of those, patients were treated with HDC (n = 264), LDC (n = 259), C (n = 353), or RT alone (n = 459). Median OS (years) was 5.61 (95% CI = 4.58-7.69) for HDC, 3.7 (95% CI = 3.1-4.79) for LDC, 3.1 (95% CI = 2.48-3.86) for C, and 1.36 (95% CI = 1.19-1.58) for RT, respectively. OS was significantly greater for HDC than for LDC (HR = 1.35, 95% CI = 1.06-1.72, p= 0.02), C (HR = 1.41, 95% CI = 1.12-1.76, p= 0.003), or RT (HR = 2.1, 95% CI = 1.68-2.61, p= < 0.001). Treatment with HDC compared to LDC was not associated with increased prevalence of dysphagia or neutropenia. HDC was associated with hearing loss when assessed at 9-12 months post-diagnosis ( p =0.03). Conclusions: In SEER-Medicare beneficiaries with PULA-HNSCC of the OPC, HP, or L, OS was significantly better for HDC than LDC when accounting for baseline clinical and demographic characteristics and propensity score weights. Toxicities were similar between regimens, except for an increased incidence of the late acute toxicity of hearing loss in HDC. A regimen of HDC improves OS, but needs to be carefully assessed against increased toxicity risk, with hearing loss in particular.

Sign in / Sign up

Export Citation Format

Share Document